Made available by Hasselt University Library in https://documentserver.uhasselt.be

cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis

Peer-reviewed author version

VANDORMAEL, Patrick; Verschueren, Patrick; DE WINTER, Liesbeth & SOMERS, Veerle (2016) cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis. In: IMMUNOLOGIC RESEARCH, 65 (1), pag. 307-325.

DOI: 10.1007/s12026-016-8839-1 Handle: http://hdl.handle.net/1942/23324

cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis

Patrick Vandormael¹, Patrick Verschueren², Liesbeth De Winter¹ and Veerle Somers^{1,#}

 ¹ Hasselt University, Biomedical Research Institute and Transnationale Universiteit Limburg, School of Life Sciences, Diepenbeek, Belgium
 ² Skeletal Biology and Engineering Research Center, KU Leuven Department of Development and Regeneration, Herestraat 49, 3000 Leuven, Belgium

* Corresponding author:
Prof. dr. Veerle Somers
Hasselt University
Martelarenlaan 42
3500 Hasselt, Belgium
Tel: 003211269202
Email: <u>veerle.somers@uhasselt.be</u>

Keywords

Autoantibody, rheumatoid arthritis, treatment, biomarker, theranostic, phage display

Acknowledgements

This study is supported by Hasselt University, Transnationale Universiteit Limburg and KULeuven. We thank all members of the CareRA study group, Veerle Stouten and Johan Joly, and show our gratitude to all participating patients.

Conflict of interest

The authors declare that they have no conflict of interest.

Abstract

Rheumatoid arthritis (RA) is the world's most common autoimmune disease mainly characterized by a chronic inflammation of multiple synovial joints. Rheumatologists now have a whole range of treatment options including glucocorticoids (GCs), classical synthetic and biological disease modifying antirheumatic drugs (cs- and bDMARDS), resulting in a tremendous improvement of treatment outcomes for RA patients over the last two decades. Despite this progress, the choice of treatment regimen to achieve stable remission at the individual patient level still largely depends on trial and error. In this review, the need for novel theranostic markers that can predict a patient's response to methotrexate, the standard first-line csDMARD treatment, is discussed. Like in many autoimmune diseases, the majority of RA patients form a whole range of autoantibodies. We aim to find novel theranostic autoantibody markers using Serological antigen selection (SAS), a high-throughput technique that uses cDNA phage display to identify novel antigen targets. We have constructed a barcoded cDNA phage display library from the synovial tissue of three RA patients by fusing cDNA products to the filamentous phage minor coat protein VI. This library contains a large proportion of full length genes and gene fragments that are cloned in frame with the phage gene VI. By screening this library for antibody reactivity in serum samples of patients from the CareRA trial, which compared different intensive treatment strategies based on csDMARDs and a step-down GC schedule, our cDNA phage display library has great potential for the discovery of novel theranostic autoantibody biomarkers.

Introduction

Rheumatoid arthritis (RA) is an autoimmune disorder that mainly affects the peripheral synovial joints. In current clinical practice, the application of an intensive treatment regimen early in the disease process aims at reducing inflammation as soon as possible to avoid damage and functional decline. Despite the fact that treatment options for RA patients have improved enormously the last decades, leading to disease remission in many patients, a true cure is still lacking. Furthermore, for each treatment option, a significant proportion of patients remains non-responsive and finding the right treatment for an individual RA patient still largely depends on trial and error. Therefore, the application of truly personalized medicine in RA is dependent on biomarkers that can predict a patient's response to different therapeutic regimens.

About two thirds of RA patients form autoantibodies, rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPA), which are used as serum biomarkers in the diagnostic process and are part of the classification criteria issued by the American College of Rheumatology (ACR) and the European League Against Rheumatism in 2010 [1]. The measurement of circulating autoantibodies is also an important tool in the classification criteria of many other autoimmune diseases such as antiphospholipid syndrome (APS) [2], systemic sclerosis (SSc) [3] and systemic lupus erythematosus (SLE) [4]. The characteristics of autoantibodies explain their popularity as biomarkers: they are easily accessible as secreted molecules in the blood where they can accumulate to high titers, they are stable biomolecules with a high-affinity for their target antigens and show a high disease specificity. With the discovery of ever more autoantibodies with diagnostic value, autoantibody profiles can be determined, allowing for sub-classification of autoimmune diseases, which are often heterogeneous in nature [5-7]. Furthermore, the use of prognostic and theranostic autoantibodies, that respectively predict how disease will progress in particular patients or whether a patient will respond to a certain treatment, or even predict the most efficient therapy before the intervention is initiated, is gaining increasing attention (reviewed in [8]).

Autoantibodies have been described against most biomolecules including DNA, lipids, carbohydrates and proteins. The subcellular localization of the antigenic targets is not restricted to the cell surface or the extracellular environment, since many autoantigens have been found in the nucleus and the cytoplasm [9]. Autoantibodies against intracellular targets could result from exposure of intracellular antigens upon apoptosis. On the other hand, antibodies generated in response to pathogens can also show cross-reactivity to intracellular antigens via molecular mimicry [10,11]. The presence of autoantibodies extends beyond their role as biomarker since several autoantibodies have been described to be drivers of disease pathogenesis (reviewed in [12]). In the collagen antibody-induced arthritis (CAIA) animal model for RA, antibodies against collagen type II are injected in naïve mice, inducing a rapid-onset arthritis that involves neutrophil invasion, pannus formation and erosions of cartilage and bone in the inflamed paws [13,14]. Although intracellular antibody reactivity has been described, its pathogenic role is not clear. Uptake and transfer to the cytoplasm of antibody-coated virus particles has been shown to induce an innate immune response via the cytoplasmic Fc receptor, tripartite motifcontaining protein 21 (TRIM21) [15,16]. However, it is not clear whether such cytoplasmic antibodies could also target intracellular targets in autoimmune disease. Alternatively, autoantibodies formed against intracellular antigens might also function through crossreactivity with extracellular antigens.

Multiple high throughput methods exist to discover the immunogenic profile against which autoantibodies are formed. Linear epitopes can be determined using technologies such as peptide arrays [17], peptide phage display [18] and phage immunoprecipitation sequencing (PhIP-Seq) [19,20] while conformational epitopes of novel autoantigens can be found by probing against full length proteins on protein arrays [21] or using cDNA phage display [22]. We have constructed a cDNA phage display library that represents the antigenic repertoire of three different RA patients. This library can be used to identify novel targets of autoantibodies that predict disease progression or therapy response in RA patients. Such prognostic and theranostic biomarkers will allow for a personalized disease management and better treatment outcomes.

RA: a heterogeneous disease based on serological markers

RA is an immune mediated, chronic systemic inflammatory condition mainly affecting the joints [23]. Clinically this disease is characterized by a polyarthritis involving the small joints of hands and feet, but in many cases also the larger joints and sometimes the cervical spine. RA related joint inflammation is primarily situated in the synovium, a thin highly organized structure between the joint capsule and the joint cavity [24], responsible for providing structural support, delivering nutrients to the cartilage and the production of synovial fluid. Morphologically, the inflamed RA synovium is characterized by a mononuclear inflammatory infiltrate that is often well organized and hypertrophy of the synovial lining layer containing fibroblasts and macrophages. If left untreated joint inflammation in RA can lead to destruction of cartilage and bone. Apart from being painful, RA related arthritis leads to considerable loss of joint function, at first directly related to inflammation but later also as a consequence of tissue damage in case of insufficient treatment. The disease burden of patients with RA is however not limited to joint complaints. Many patients with RA suffer from fatigue and they are prone to comorbidities like depression or anxiety, cardiovascular disease and osteoporosis [25-27]. Based on the phenotypical description above, which most patients have in common, one might consider RA to be a disease with a similar, predictable natural evolution leading to a similar treatment response in different individuals, but this is far from true. Already at the clinical level, the syndrome called RA is not so uniform. Apart from signs of inflammation, the serum of a majority of RA patients contains the characteristic markers of autoimmune activation, RF and ACPA. Still, a subset of patients can be diagnosed and even classified with RA based on clinical signs and symptoms without the presence of RF or ACPA. This so-called seronegative RA is more and more considered to be a separate disease entity, sharing phenotypical characteristics with the more classical seropositive RA, but having a completely different underlying pathophysiology with different genetic and environmental risk factors and by consequence also a different natural disease course and responsiveness to treatment [28]. The cellular and molecular background of the differences between seropositive and seronegative RA is actively being explored but until now remains largely unknown.

Traditionally RF/ACPA seropositive RA patients are expected to suffer a more severe disease course in terms of cumulative disease activity, joint destruction, disability, comorbidities and mortality [29]. Moreover, a subgroup of seropositive patients develops extraarticular manifestations of RA such as nodules, interstitial lung disease or vasculitis [23]. RF is an antibody directed against the Fc portion of immunoglobulin G (IgG) [30] and is found in 69-80% of RA patients [31,32] but is also detected in elderly and in other chronic inflammatory conditions limiting RA-specificity to no more than 85% [32]. Binding of RF to Ig-Fc is mediated at an unconventional part of the B cell receptor leaving space for other antigens to be bound and presented to T cells [33]. Immune complexes formed by RF activate B cells and complement, thereby triggering the release of chemotactic factors and recruiting other inflammatory cells [34]. By this pro-inflammatory mechanism of action, RF-positive patients have a worse outcome [31,35]. Most but not all patients positive for RF, are also positive for ACPA. In contrast to RF, ACPA are highly specific (>95%) for RA with a sensitivity of approximately 70% [32,36]. ACPA are antibodies recognizing citrullinated proteins, which are formed by the post-translational modification of arginine residues into citrulline. ACPA are detected years before symptom onset and have proven to be useful in the prediction of progression from undifferentiated arthritis (UA) to RA [37-39]. Testing for ACPA provides important prognostic information, as ACPA-positive patients are more likely to develop extraarticular manifestations [40,41] and have more radiological progression [42,43]. These observations from clinical assessment were supported by the finding that antibodies against citrullinated vimentin directly bind to the osteoclast surface and induce osteoclastogenesis and bone resorption *in vitro* and *in vivo* [44]. The bad prognostic outcome for ACPA-positive patients requires aggressive intervention as soon as possible, and clinical studies have demonstrated that ACPA-positive and ACPA–negative patients respond differently to treatment with methotrexate [45] or rituximab [46].

Recently, a novel antibody system has been discovered, anti-carbamylated protein (anti-CarP) antibodies, directed towards another post-translational modification [47,48]. Carbamylation is the conversion from lysine to homocitrulline by cyanate. The production of cyanate is induced by myeloperoxidase, released by neutrophils in inflammatory conditions. Higher cyanate concentrations have been detected after smoking, the most prominent environmental risk factor for the development of RA [49]. Although structurally homocitrulline resembles citrulline, and some overlap was found for the two antibody systems, ACPA and anti-CarP recognize their own specific peptides. Anti-CarP antibodies are found in 45% of RA patients and 16-30% of ACPA-negative RA patients, and they are associated with more severe joint damage, also within these ACPA-negative RA patients [47].

Novel autoantibodies in RA were previously identified by serological antigen selection (SAS) [50] and recently validated in two large independent study populations [51]. Antibodies to two Hasselt University (UH) peptides, UH-RA.1 and UH-RA.21, were most promising as they were found in up to one-third of early RA patients. Addition of these novel antibodies to the current diagnostic markers, RF and ACPA, reduced the seronegative population from 38% to 29-32%, and could thus contribute to a better early diagnosis of RA. The potential of combined antibody testing was further illustrated by involving anti-CarP antibodies in the Early Arthritis Clinic (EAC) cohort: anti-CarP status was positive for 12% of early seronegative RA patients, thus reducing the serological gap from 38% to 34%. However, anti-CarP combined with autoantibodies to UH-RA.1 and UH-RA.21 further reduced the gap down to 27%. Next to a diagnostic potential, also correlations with prognostic characteristics were demonstrated: whereas antibodies against UH-RA.1 were related to sustained DMARD-free remission in the EAC cohort, pointing towards a better outcome, antibodies against UH-RA.21 were associated with worse disease based on associations with the presence of erosions, elevated ESR and a higher tender joint count.

Other antigenic targets in RA that have been described, include antibodies directed against arginine deiminase 4 (PAD4), calpastatin, phospholipids, α -enolase, stress proteins (binding immunoglobulin protein (BiP or p68)), glucose-6-phosphate isomerase, heterogeneous nuclear ribonucleoprotein A2/B1 (anti-RA33), v-Raf murine sarcoma viral oncogene homologue (BRAF) and several cartilage proteins (collagen, fibronectin, cartilage oligomeric matrix protein), summarized in [52-55]. Most of these autoantibodies still require validation studies in larger cohorts to determine their exact role.

Different treatment regimens for RA

Treatment of RA patients has become much more successful over the last decades thanks to the development of new treatment strategies and more targeted therapeutic agents called biologicals [56]. The efficacy of RA treatment can be evaluated based on different biopsycho-social outcome parameters, but biological disease control remains the quintessence of any pharmacological intervention and it is also a prerequisite for psychosocial wellbeing of most individuals with RA. The current biological target of RA treatment is remission, which can be defined in many different ways but is in essence the absence of any significant disease activity [57]. Most rheumatologists agree there is a window of opportunity for successful introduction of RA treatment, probably consisting of the first 3-4 months after symptom onset, during which therapeutic interventions are particularly effective, resulting in better chances of achieving long-term sustained remission, avoiding irreversible biological disease consequences and preserving optimal functionality as well as structural joint integrity [58]. Based on this knowledge, current guidelines prescribe that RA has to be treated early, intensively and to target [59-61].

Methotrexate (MTX) at sufficiently high dosages is considered the initial treatment of choice, but given its slow onset of action it is combined preferably with medication allowing a more rapid control of inflammation. In daily practice, many patients with early RA receive MTX with low dosages of glucocorticoids (GC) for a couple of weeks and therapy is adapted depending on the effect (step-up). On the other hand, so-called Cobra strategies (based on the Dutch acronym "combinatietherapie bij reumatoide artritis") combining classical synthetic (cs) disease-modifying antirheumatic drugs (DMARD) with a step-down bridge schedule starting from moderate or high dosages of GC were demonstrated to be superior in several randomized controlled trials and perfectly feasible in an observational cohort [62-66]. Still, csDMARDs do

not fully suppress disease progression in all patients and combination therapies are regularly accompanied by an increase in toxicity and adverse effects [67-69].

Inadequate response and toxic effects are the major reasons to switch from csDMARDs to biological (b) DMARDs or biologicals, recombinant protein drugs copying the effects of natural *in vivo* substances. The first bDMARDs were chimeric monoclonal antibodies aimed at tumor necrosis factor α (TNF- α), the major pro-inflammatory cytokine involved in RA pathology and for which targeting in both mice and humans has been shown to ameliorate disease [70-73]. TNF- α inhibitors approved for treatment of RA are infliximab, etanercept, adalimumab, golimumab and certoluzimab, all proven to be highly effective, especially in combination with MTX [74]. New bDMARDs beyond TNF- α inhibitors target cytokine pathways (anakinra, anti-IL-1RA and tocilizumab, anti-IL-6 receptor), B cells (rituximab, anti-CD20) and T cell activation (abatacept, CTLA4-antibody fusion protein targeting CD80/CD86 on antigen-presenting cells) [75-78].

bDMARDs combined with MTX were also shown to be more efficacious than csDMARD monotherapy in early RA, but until now their effectiveness was only rarely directly compared with step-down Cobra strategies [79]. The available evidence suggests that the remission rate and preservation of structural joint integrity on X-ray in patients treated with TNF- α blockers is not superior compared to individuals with early RA treated with high-dose GCs combined with MTX [80,63]. There is however an important price difference between both strategies and until now it remains unclear if bDMARDs can be discontinued without loss of effect after being used temporarily as remission-inducing agents [81]. For these reasons, current guidelines do not recommend bDMARDs as first-line treatment for early RA except in special cases with an unfavorable prognostic profile. Consequently, in many countries

bDMARDs are not reimbursed as first-line treatment for RA and in Belgium they can only be introduced in case of failure of two csDMARDs. Cobra-like treatment regimens therefore seem the obvious first choice for remission induction in early RA but there are still important implementation problems because of practical issues and doubts from patients and doctors related to high GC dosages and the need to combine csDMARDs in these schedules [82-84]. Moreover, it remains unclear if patients with a less severe disease profile according to the present standards, for instance seronegative patients without bone erosions and with low disease activity, should receive the same treatment as patients with a severe risk profile [29,85].

Lack of treatment response for patient subpopulation

Despite the success of current therapeutic strategies, resulting in remission rates of up to 70%, there is still an unmet need in a large proportion of early RA patients. A non-responsive treatment population can be found for csDMARDS treatment regimens [86], and despite their high effectiveness in many patients, bDMARDS such as TNF- α inhibitors also give variable therapy responses and still a considerable number of patients do not respond [87,88]. Of course the remaining important delay in diagnosis and appropriate treatment initiation [89-91], difficulties with the implementation of sufficiently intensive treatment schedules [82-84] as well as adverse reactions to DMARDs, comorbidities, discrepancies in treatment goals between patients and health professionals [89] and psychosocial factors can be held partly responsible for this, but the leading cause of the unmet need remains insufficient biological disease control with current therapeutics. It might be that current therapies are simply not sufficiently potent to deal with the particular pathophysiological processes responsible for persistent disease activity in certain individuals or that they fail to hit the right targets. For this reason, current treatment paradigms still need further improvement and the place of novel therapeutics early in the disease

course needs to be evaluated. An important condition for a cost-effective implementation of such new treatment approaches would of course be a more successful patient stratification.

One of the main reasons why RA treatment is still suboptimal is that the therapeutic response is unpredictable [92]. In practice, many rheumatologists use the same initial treatment strategy for all RA patients, consisting of methotrexate temporarily combined with a low dose of GCs, stepping up to combination therapy or biologicals in case of an insufficient response [65,93]. Even if they attempt to avoid under- or overtreatment in individual patients by taking into account traditional risk factors, they are not very successful at this, probably because the performance of these prognostic markers is reduced in case of an intensive treatment approach such as advocated in the guidelines [94]. This means that finding the right treatment schedule for an individual RA patient is still pretty much a question of trial and error and given the slow onset of effect inherent to many anti-rheumatic therapies, it can take quite some time before sufficient disease control is achieved. This is not only a question of treatment efficacy but also of drug toxicity and side effects at the individual patient level. Inevitably, until today many patients experience prolonged periods of insufficient symptom control, important discomfort and impaired quality of life as a consequence of this empirical treatment approach. Moreover, the delay in initiating the appropriate therapy caused by this trial and error strategy can be a reason for individual RA patients to miss the window of opportunity for effective therapeutic intervention [90,95,96]. This means their chances of achieving sustained disease remission, a prerequisite for optimal functionality and structural joint integrity, are compromised and they are more at risk for comorbidity, chronic disease behaviour and other psychosocial consequences of the disease.

A more personalized treatment approach based on a more effective patient stratification would not only be of benefit to individual patients and their doctors, but would probably also be more cost-effective from a societal point of view, even considering the potential extra costs for the introduction of expensive novel therapies earlier in the disease course in the minority of RA patients at risk of an insufficient response to intensive treatment regimens based on csDMARDs and GCs like the Cobra Slim regimen [56]. Currently, the traditional risk factors, even when used in matrices, are not very helpful in this respect [92]. The classical diagnostic markers, RF and ACPA have been studied extensively for their theranostic potential in the context of MTX treatment. For RF status, no predictive value of MTX therapy response has been found and despite some conflicting results, also ACPA status before the onset of treatment does not seem to correlate with the effectiveness of MTX (reviewed in [97]). Some studies have reported a lower treatment response for ACPA-positive patients but these might reflect the higher disease activity of ACPA-positive patients. Recently, a number of studies have reported on novel biomarkers to predict the treatment outcome of MTX therapy. Quantification of T-cell subsets using fluorescence-activated cell sorting (FACS) of 108 early RA patient samples at baseline showed that remission in response to MTX monotherapy was associated with a higher frequency of naïve CD4+ T-cells compared to healthy controls [98]. Recently, Peres et al described [99] that MTX treatment response can be predicted at baseline using flow cytometric determination of the ectonucleotidase CD39 on the cell surface of regulatory T-cells (Tregs). Patients that did not reach remission after MTX monotherapy (disease activity score DAS28> 4,0) express a significantly lower level of CD39 on Tregs compared to healthy controls and MTX-responsive RA patients. These studies are able to distinguish between MTX responders and non-responder using flow cytometry and contribute to the biological understanding of treatment response. However, a serological marker would be more easily applicable in clinical routine testing. The acute phage protein haptoglobin is locally elevated in RA synovial fluid and arthritic tissue. Moreover, baseline haptoglobin serum levels are significantly higher in patients that do not show a MTX response after 12 weeks [100]. Finally, a *post hoc* analysis of serum samples from the Swedisch Farmacotherapy (SWEFOT) trial demonstrated a poor response to MTX monotherapy in patients that are positive for survivin [101], a proto-oncogene that has also been shown to be upregulated in the serum of preclinical phase RA-patients [102]. Overall, a number of promising theranostic markers for MTX response exist, but these generally have only been tested a limited numbers of patients and await validation in larger independent patient cohorts. Therefore, the need for novel clinically applicable biomarkers that can predict MTX response before the onset of treatment remains high. Discovery of novel, more sophisticated theranostic models could result in an improvement of the global quality of RA care, reducing costs for extra medication, (para-) medical consultations and hospitalizations to deal with insufficient disease control, not to forget its consequences in terms of adverse events, comorbidity, psychosocial wellbeing, orthopedic surgery need and vocational/professional participation [56].

Screening for novel theranostic autoantibody markers using serological antigen selection

As mentioned above, there is an urgent need for novel theranostic biomarkers in daily clinical practice since there is evidence that the traditional serological markers for RA (RF and ACPA) do not perform well enough for the stratification of patients with RA, especially in view of treatment allocation [85]. To be relevant for clinical practice the discovery of new serological biomarkers should ideally be based on the analysis of samples derived from a well-defined and representative patient population that is followed prospectively with regular documentation of disease activity, functionality and joint damage [92]. Patients in such a cohort should

preferentially be treated in a highly standardized way and according to the current treatment paradigm based on rapid remission induction followed by a treat to target approach, certainly for the discovery of novel prognostic and theranostic biomarkers. In the CareRA trial, a pragmatic randomized controlled trial involving 400 early RA patients, both high-risk as well as low-risk patients based on the current prognostic standards, were treated according to a strict protocol reflecting current international treatment recommendations [85,86] (Figure 1). Throughout the trial, an extensive clinical dataset and serum samples at baseline and follow up samples throughout a two year period after treatment initiation, were collected. Such a collection of well-defined serum samples will allow us to probe for different autoantibody profiles using serological antigen selection (SAS), a powerful high-throughput screening technology to identify novel autoantibody targets using cDNA phage display. Of particular interest will be the use of baseline samples to find markers that predict positive or negative response to the Cobra treatment regimens, while the use of intermediary samples can be used to find novel markers that predict disease relapse in patients that achieved early remission.

1 cDNA phage display

Phage display was first described 30 years ago by George Smith [103] and is now a commonly used technique that uses the expression of exogenous proteins or peptides on the surface of phage particles to probe for protein-protein interactions (reviewed in [104,105]). Different types of phage are used for phage display including the filamentous M13 phage, the temperate λ phage and the lytic T7 phage. One of the main strengths of phage display is the use of large diversity phage libraries, which can contain 10⁶-10⁷ independent clones for cDNA libraries [106-108] and up to 10¹⁰ clones for random or overlapping peptide libraries. This increases the chance to find relevant, high-affinity interacting proteins, which is required for applications like epitope mapping of antibodies. Furthermore, the direct link between the

protein expressed on the phage surface and the genetic material inside the phage particle allows sequential rounds of target selection and amplification and easy target identification by DNA sequencing.

Filamentous phage can only infect bacteria expressing F-pili to which they bind for entering the cell. Upon entry, the phage uses the bacterial machinery for replicating its circular genome and synthesizing proteins required for phage packaging. Assembly and release of new phage particles occurs at the bacterial plasma membrane and does not involve cell lysis. The M13 filamentous phage consists of a circular single stranded DNA genome surrounded by a protein coat composed of five different proteins (reviewed in [105]). The protein coat has a rodlike, elongated shape with several thousand copies of the major coat protein pVIII covering the length of the phage, while the two ends of the filament are capped 3 to 5 copies of each of the minor coat proteins pIII, pVI, pVII and pIX. Phage display libraries have been made using each of the five coat proteins, but fusion to the minor coat proteins pIII and the major coat protein pVIII are most commonly used [109]. In most phage display systems, the fusion proteins are expressed from phagemid vectors. These carry a bacterial and phage origin of replication, a phage packaging signal, an antibiotic resistance gene and the phage coat protein that will carry the fusion [110]. The other proteins required for phagemid replication and packaging are provided by superinfection with a helper phage. To ensure that the phagemid is preferentially packed in the secreted phage particles, replication deficient helper phage like M13KO7 is often used [111].

Fusion to pIII and pVIII is almost exclusively to the N-terminus. This orientation does not allow cloning of full length cDNA since the endogenous stop codon will prevent formation of a fusion protein. However, cDNA synthesis using internal priming with random hexameric primers or fragmentation of the cDNA molecules can generate cDNA fragments that lack the natural stop codon, allowing N-terminal fusion. Such a cDNA library can be further enriched for in-frame clones using the so-called Hyperphage [112,113]. This is a helper phage that lacks a wild type pIII gene, so functional phage particles can only be formed if the cDNA fragment is cloned in frame with the downstream gene III. Display of a cDNA library on pIII can also be achieved using the indirect Jun-Fos system [114]. This system relies on the strong association of Jun, which has the library inserts cloned to its C-terminus, and its interaction partner Fos, fused to pIII.

On the other hand, since pVI is the only phage coat protein with its C-terminus facing outward, it is highly suitable for direct cloning of full length cDNA fusion libraries. Since phage display using pVI fusion is monovalent, generating phage particles with one fusion protein per phage particle [115], it allows for the identification of high-affinity interactions. This display method has been successfully used for the isolation of serine protease inhibitors from a hookworm cDNA library [115], and a series of reports from our research group describe the construction and use of patient- and tissue-specific pVI cDNA libraries expressing colorectal cancer tumor antigens [116] and autoantigens of the autoimmune diseases RA [107], MS [22,117] and clinically isolated syndrome [118]. Recently, our research group has also reported on the construction of a novel human spinal cord cDNA phage display library [119].

2 Serological antigen selection

The autoantibody profile of a specific patient (sub)population can be determined using a method called serological antigen selection (SAS). Here a high diversity disease- or tissue-specific cDNA phage display library is used to identify the antigenic targets that elicit an antibody response (Figure 2). Depending on the application the antibody markers will be used for, patient

sera of a specific (autoimmune) disease or a specific subpopulation, such as patients with early diagnosis, poor prognosis or positive or negative response to a particular treatment regimen, can be chosen. These patients should represent the general characteristics of the entire patient population including age, gender and possible genetic markers. Usually 5 to 10 patient sera are selected and pooled for the panning procedure. SAS has been successfully used to identify novel candidates in the antigenic repertoire of colorectal cancer [116], MS [22,120,117], CIS [118,121], RA [50] and spinal cord injury (our unpublished data). The cDNA phage display libraries used in these studies contain a primary diversity in the range of 10⁶-10⁷ bacterial phagemid clones [106-108]. This bacterial library is infected with M13KO7 helper phage and phage particles displaying the antigenic repertoire are assembled and released in large numbers. This phage library is panned against the autoantibodies present in the sera of a selection of patients of interest. Pooled patient serum is incubated with the phage library in solution allowing complex formation between the displayed human proteins and serum autoantibodies. After immunoprecipitation of these complexes, bound phage is eluted and amplified by reinfecting pilus-bearing bacteria. Multiple rounds of this positive selection are repeated in order to amplify the specific binding variants. Non-specific binders are eliminated in a final negative selection round where those antigens that bind to antibodies from age- and gender-matched healthy control sera, are removed. Finally, the resulting antigenic profile can be determined using DNA fingerprinting and sequencing of the cDNA inserts cloned behind gene VI.

The use of a human cDNA phage display library derived from disease-specific tissue to discover novel autoantigens offers several advantages compared with the use of human protein arrays. Since a cDNA library covers the transcriptome of the tissue it is isolated from, it contains autoantigens that are specifically upregulated in disease-related tissues or cell types isolated from patients with active disease. This has been shown in anti-neutrophil cytoplasmic antibody

(ANCA) positive vasculitis patients, where the expression of the autoantigens proteinase3 and myeloperoxidase was specifically upregulated in neutrophils [122]. Comparison of cDNA libraries from MS patients and healthy controls showed a differential upregulation of several described autoantigens in the MS patient-derived cDNA library [123]. Furthermore, patient material allows for the isolation of disease-specific sequence variants while protein arrays are usually limited to the canonical gene sequences. Glucose-6-phosphate isomerase (GPI) [124] and heterogeneous nuclear ribonucleoprotein complex A2 (hnRNP-A2) [125] autoantibodies have been reported in several arthritic diseases including RA. Sequence variants that lead to partial deletions of the GPI gene [126] and hnRNPA2/B1 splice variants that lack exon 9 [127] are more antigenic and induce a more pronounced autoantibody response. Finally, cDNA phage display libraries are often cloned in a phagemid that uses cloning in three different reading frames to allow the cDNA to be expressed in-frame with the phage coat protein in one out of three clones [106]. Therefore, two thirds of the library consists of out of frame fusions that generate random peptide sequences. This results in a phage display library that combines the expression of proteins and peptides that respectively allow the isolation of conformational epitopes and linear epitopes or mimotopes [128,129].

3 A well-defined patient population is required for SAS

In order to identify novel autoantibody markers with theranostic value, we can rely on serum samples from the well characterized CareRA patient cohort. The CareRA study is a broad research project anchored to a pragmatic multicenter randomized controlled trial in collaboration with 12 rheumatology practices and almost 400 participating patients [86]. Patients were stratified to risk groups based on classical prognostic factors (RF/ACPA, disease activity and erosions) (Figure 1). High-risk patients (n=300) were randomized to one of three treatment arms consisting of different Cobra variants (classic/avant-garde/slim) and low-risk

patients (n=100) either to a step-up from MTX monotherapy or a step-down Cobra slim therapy. Treatment in all arms was adjusted if needed to a target of low disease activity. From the CareRA trial we learned that all Cobra regimens resulted in very high remission rates (70%), that combinations of csDMARDs (Cobra avant-garde and classic) were not superior to MTX alone (Cobra slim) when given together with a step-down GC regimen, that high initial prednisone dosages (60 mg) were not superior to moderate dosages (30 mg) for remission induction and that Cobra slim showed less adverse events than csDMARD combinations in high-risk early RA [86]. In low-risk RA patients Cobra slim resulted in a shorter time to remission without more adverse events compared to step-up therapy [85]. Based on these results from the CareRA trial, applying the treat to target principle and pending better risk stratification, Cobra slim can be proposed as an effective one-size-fits-all initial treatment solution for all RA patients and a benchmark for future cost-effectiveness trials with novel therapeutics.

Starting from this sample collection there are many opportunities for the discovery and validation of novel biomarkers for diagnosis and classification, but also for theranostic purposes. Today however, for us the most urgent unmet need in the clinic is a tool for rapid identification of early RA patients at risk of an insufficient response to a combination of csDMARDs combined with GCs, like the Cobra Slim regimen, which we consider the gold standard [85,86]. There is ample evidence that the response during the first weeks after treatment initiation is predictive of the disease course thereafter, more or less irrespective of the initial treatment choice [56]. Therefore it should be possible to discover and validate biomarkers predictive of the response to treatment according to the present standards by comparing baseline serum samples from CareRA patients achieving remission or not, after 16 weeks of treatment.

4 Construction of a novel RA cDNA phage display library

We have constructed a cDNA phage display library that represents the transcripts expressed in human knee synovial tissue (Figure 3). Synovium was obtained from three female RA patients that have undergone knee replacement surgery. Since there might be interpersonal variation with respect to the expressed antigens, the incorporation of synovial material from multiple patients increases the chance to find relevant antigenic sequences. Total RNA was extracted and purified from synovial tissue of the different RA patients. RNA integrity was confirmed on a 2100 Bioanalyzer (Agilent) using an RNA Nano chip and the Eukaryote Total RNA Nano program. Messenger RNA (mRNA) expressed in the tissues was converted into cDNA using an oligo (dT)22 primer containing a XhoI restriction site (Maxima H-minus double stranded cDNA synthesis kit, Thermo Fisher). The Maxima H-minus reverse transcriptase lacks RnaseH activity, and is more stable at higher temperatures resulting in a higher processivity and a higher chance to cover the entire open reading frame, starting from the poly-A tail. The oligo(dT) primer used, was modified with a VN anchor at the 3' end, where V stands for dA, dC, or dG and N for dA, dC, dG or dT. Such an anchored oligo(dT) primer only allows primer annealing at the very 5' end of the poly-A tail, leading to reduced poly-A slippage and a more efficient cDNA synthesis [130]. Each of the three pools of blunt-ended, double-stranded cDNA of the different tissue donors, was then ligated with its unique adaptor. These consisted of a free EcoRI overhang, a NotI restriction site and either a SalI, AgeI or ClaI restriction site. The difference in sequence between the latter three enzyme recognition sites can be used as a molecular barcode afterwards to identify the donor tissue the cDNA originated from. The total cDNA mixture was size-fractionated using agarose gel electrophoresis and cDNA inserts ranging from 200 to 10,000 bp were directionally cloned in the pSPVI-A, pSPVI-B and pSPVI-C phagemid vectors using the EcoRI an XhoI restriction enzymes. Each pSPVI vector has a different reading frame, which allows cloning of the cDNA insert in frame with the M13 phage gene VI in one of the three vectors [106]. The protein encoded by the human cDNA is then expressed as a C-terminal fusion to the M13 minor coat protein pVI. The entire cDNA library was electroporated to F pilus-expressing TG1 *Escherichia coli* cells resulting in a total primary diversity of 9.0×10^6 bacterial colonies.

The quality of our primary cDNA phage display library was investigated by sequencing the inserts cloned behind gene VI of 70 randomly selected clones. A good distribution between each of the three reading frames of the pSPVI-A, pSPVI-B and pSPVI-C phagemid vectors was found (Figure 4a). Twelve clones (17,1%) contained no insert leading to a slight decrease in our true library diversity. After correction for the empty pSPVI clones, we still have a diversity of 7,47 x 10^6 insert containing clones. Since this library contains the cDNA inserts of three different tissue donors, cloned into three different reading frames, each donor has the potential for 0,83 x 10^6 clones that are in frame with the M13 gene VI. With an estimated 19,000 to 20,500 protein coding genes in the human genome [131,132], each gene approximately has a 40-fold coverage on average. With such a large library diversity, also genes with lower expression levels in the synovium are likely to be represented in our library.

Each of the 58 remaining insert-containing clones could be traced to one of the three tissue donors using our patient-specific adaptors, showing that each donor was equally represented in the entire library (Figure 4b). Inserts were compared to human reference mRNA or genomic sequences using the Basic Local Alignment Search Tool (BLAST) on the NCBI website (<u>www.ncbi.nlm.nih.gov/BLAST</u>) (Table 1). This allowed the identification of the mRNA the insert originated from and the region of the transcript that was fused to gene VI (Figure 4c). Of the insert containing clones, 21 contained a sequence starting in the 5' untranslated region (UTR) of the cDNA (36,2 %), 16 in the coding region (27,6 %) and 12 in the 3' UTR (20,7).

For 9 clones, the insert did not originate from mRNA but from ribosomal RNA (rRNA) (5 clones, 8,6%) or genomic DNA (4 clones, 6,9%).

In a large proportion of clones, the cDNA insert was cloned in frame with the M13 gene VI (Table 1). This was the case for 42,9 % of the 5'UTR fusions and 50% of the fusions to the coding region. The clones that had an in-frame fusion to the 5'UTR contained part of the translated 5'UTR followed by the full length protein, which could range in size between 91 and 685 amino acids (aa). In-frame fusions to the coding region could be found in different parts of the open reading frame, resulting in fusion proteins with a size between 10 and 354 aa. The remaining clones contained an out of frame fusion or fusion to a non-coding region, resulting in fusion constructs with a random peptide sequence between 1 and 147 aa. Approximately one in two (26/49, 53,1%) of the cDNA clones encoded for proteins with a cytoplasmic localization such as the generally expressed beta actin (ACTB), alpha 1 tubulin (TUBA1C) and several ribosomal protein genes. Genes encoding ribosomal protein genes represented the largest fraction of our sample (13/49, 26,5%). Subunits of ferritin (FTH1, FTL), a cytoplasmic protein involved in iron storage, have been isolated four times, originating from two different tissue donors. Ferritin has been found to be specifically upregulated in RA synovium [133,134]. Also of interest is the expression of S100A9, a subunit of the cytoplasmic calprotectin protein complex. Calprotectin is a calcium-binding complex mainly expressed in macrophages and neutrophils. Under a number of inflammatory conditions such as RA, Crohn's disease and MS, it is also released into the extracellular environment where it acts as danger associated molecular pattern (DAMP) (reviewed in [135]). In RA patients, its elevated levels in both serum and synovial fluid correlate with the degree of inflammation and joint damage [136]. Approximately 18% (9/49) of the insert containing clones encoded extracellular proteins such as the extracellular matrix (ECM) proteins collagen type I alpha 1 (COL1A1) and fibronectin 1 (FN1) and the ECM protein-modifying enzymes galactosidase beta 1 (GLB1) and lysyl oxidase-like 1 (LOXL1). Additional extracellular proteins of interest were the proteases HtrA serine peptidase 1 (HTRA1) and Cathepsin B (CTSB) and protease inhibitors serpin peptidase inhibitor, clade F (SERPINF1) and clade G (SERPING1). HtrA1 and CtsB are secreted by RA fibroblast-like synoviocytes (FLS) and contribute respectively to extracellular matrix degradation and FLS migration and invasion [137-139]. SERPINF1 mutants have been shown to lead to osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass and bone fragility [140] while SerpinG1 is responsible for inhibition of the C1 component of the classical complement system [141]. Three clones encoded proteins with a plasma membrane localization, such as HLA class II histocompatibility antigen gamma chain (CD74), which is involved in antigen processing [142] and required for osteoclastogenesis induced by its ligand macrophage migration inhibitory factor (MIF) [143,144]. Finally, cDNA products were found that localize to the nucleus (10,2%), endoplasmic reticulum (6,1%), Golgi (4,1%) and one gene with unknown function and localization.

Future perspectives

Our newly constructed cDNA phage display library is a high diversity representation of the genes expressed in synovia of three different RA patients. A large proportion of this library consists of full length genes and gene fragments cloned in frame with the M13 gene VI. Therefore, this library is a tool with great potential to discover novel autoantigens for RA. The combination of this library with selected pooled sera has the potential to uncover novel autoantibody biomarkers for very different applications. The use of samples from the CareRA patient cohort will allow us to isolate novel theranostic markers in baseline sera that predict disease relapse, but also novel diagnostic markers that would identify seronegative patients.

Ethical approval: "All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards."

Informed consent: "Informed consent was obtained from all individual participants included in the study."

1. Abbreviations

Rheumatoid arthritis (RA) systemic sclerosis (SSc) systemic lupus erythematosus (SLE) anti-citrullinated protein antibodies (ACPA) collagen antibody-induced arthritis (CAIA) Non-steroidal anti-inflammatory drugs (NSAIDs) disease-modifying anti-rheumatic drugs (DMARDs) tumor necrosis factor α (TNF- α), rheumatoid factor (RF) cyclic citrullinated peptides (CCP) undifferentiated arthritis (UA) anti-carbamylated protein (anti-CarP) anti-neutrophil cytoplasmic antibody (ANCA) untranslated region (UTR)

2. Tables

Table1: sequences identified in RA cDNA library

NCBI code	cDNA identity	fusion	size fused	in frame
		type	protein (aa)	pVI
NM_000404.3	galactosidase beta 1 (GLB1)	5'UTR	685	Y
NM_000981.3	ribosomal protein L19 (RPL19)	5'UTR	376	Y
NM_002356.6	myristoylated alanine rich protein kinase C substrate (MARCKS)	5'UTR	356	Y
NM_153649.3	tropomyosin 3 (TPM3), variant 1 (TPM3)	5'UTR	266	Y
NM_002032.2	ferritin, heavy polypeptide 1 (FTH1)	5'UTR	243	Y
NM_000146.3	ferritin, light polypeptide (FTL)	5'UTR	238	Y
NM_182491.2	zinc finger, AN1-type domain 2A (ZFAND2A)	5'UTR	234	Y
NM_001017.2	ribosomal protein S13 (RPS13)	5'UTR	155	Y
NM_001024.3	ribosomal protein S21 (RPS21)	5'UTR	91	Y
NM_002032.2	ferritin, heavy polypeptide 1 (FTH1)	5'UTR	103	Ν
NM_005576.3	lysyl oxidase-like 1 (LOXL1)	5'UTR	41	Ν
NM_000992.2	ribosomal protein L29 (RPL29)	5'UTR	37	Ν
NM_001016.3	ribosomal protein S12 (RPS12)	5'UTR	37	Ν
NM_006423.2	Rab acceptor 1 (prenylated) (RABAC1)	5'UTR	34	Ν
NM_002933.4	ribonuclease A family member 1 (RNASE1)	5'UTR	34	N
NM_021104.1	ribosomal protein L41 (RPL41)	5'UTR	34	Ν
 NM_000088.3	collagen type I alpha 1 (COL1A1)	5'UTR	14	N
NM_015683.1	arrestin domain containing 2 (ARRDC2)	5'UTR	12	Ν
 NM_012423.3	ribosomal protein L13a (RPL13A)	5'UTR	11	N
	dolichyl-phosphate mannosyltransferase	5'UTR	8	Ν
_	polypeptide 3 (DPM3)			
NM_002948.3	ribosomal protein L15 (RPL15)	5'UTR	5	Ν
NM_212478.2	fibronectin 1 (FN1)	coding	354	Y
NM_006600.3	nuclear distribution protein (NUDC)	coding	322	Y
NM_031369.2	heterogeneous nuclear ribonucleoprotein D (HNRNPD)	coding	269	Y
NM_000975.3	ribosomal protein L11 (RPL11)	coding	178	Y
NM_022551.2	ribosomal protein S18 (RPS18)	coding	149	Y
NM_001357.4	DEAH-box helicase 9 (DHX9)	coding	125	Y
NM_000177.4	Gelsolin (GSN)	coding	43	Y
NM_005103.4	fasciculation and elongation protein zeta 1 (FEZ1)	coding	10	Y
NM_000062.2	serpin peptidase inhibitor, clade G (SERPING1)	coding	100	Ν
NM_001015.4	ribosomal protein S11 (RPS11)	coding	52	Ν
NM_002965.3	S100 calcium binding protein A9 (S100A9)	coding	30	Ν
NM_001101.3	actin, beta (ACTB)	coding	24	Ν
NM_002775.4	HtrA serine peptidase 1 (HTRA1)	coding	14	Ν
NM_001015.4	ribosomal protein S11 (RPS11)	coding	7	N
NM_001303114.1	tubulin alpha 1c (TUBA1C)	coding	1	Ν
NM 001011.3	ribosomal protein S7 (RPS7)	coding	1	Ν

NM_023080.2	C8orf33 (C8orf33)	3'UTR	65	N/A
NM_001908.4	Cathepsin B (CTSB)	3'UTR	53	N/A
NM_002032.2	ferritin, heavy polypeptide 1 (FTH1)	3'UTR	42	N/A
NM_014045.3	low density lipoprotein receptor-related protein 10 (LRP10)	3'UTR	27	N/A
NM_001025159.2	major histocompatibility complex, class II invariant chain (CD74)	3'UTR	14	N/A
NM_001101.3	actin, beta (ACTB)	3'UTR	14	N/A
NM_182547.3	transmembrane p24 trafficking protein 4 (TMED4)	3'UTR	10	N/A
NM_002615.5	serpin peptidase inhibitor, clade F (SERPINF1)	3'UTR	8	N/A
NM_014604.3	(human T-cell leukemia virus type I) binding protein 3 (TAX1BP3)	3'UTR	5	N/A
NM_207012.2	adaptor related protein complex 3 mu 1 subunit (AP3M1)	3'UTR	3	N/A
NM_173179.3	solute carrier family 35 (GDP-fucose transporter), member C2 (SLC35C2)	3'UTR	2	N/A
NM_015360.4	Ski2 like RNA helicase 2 (SKIV2L2)	3'UTR	1	N/A
NR_046235.1	45S pre-ribosomal 5 (RNA45S5)	rRNA	132	N/A
NR_046235.1	45S pre-ribosomal 5 (RNA45S6)	rRNA	56	N/A
NR_046235.1	45S pre-ribosomal 5 (RNA45S7)	rRNA	45	N/A
NR_046235.1	45S pre-ribosomal 5 (RNA45S8)	rRNA	41	N/A
NR_003286.2	18S ribosomal 5 (RNA18S5)	rRNA	0	N/A
	(genomic)	genomic	147	N/A
	(genomic)	genomic	15	N/A
	(genomic)	genomic	6	N/A
	(genomic)	genomic	4	N/A

3. Figure legends

Figure 1 Patient stratification and randomization in the CareRA trial

All patients that participated in the CareRA trial (n=380) were risk stratified according to the classical prognostic factors, RF/ACPA status, disease activity and erosions. The high risk patients (n=290) were randomized into three groups: Cobra classic (MTX + sulfasalazine + 60 mg prednisone tapered to 7,5 mg daily from week 7), Cobra slim (MTX + 30 mg prednisone tapered to 5 mg daily from week 6) and Cobra avant-garde (MTX + leflunomide + 30 mg

prednisone tapered to 5 mg daily from week 6). The low risk patients (n=90) were randomized into two groups: tight step-up (MTX monotherapy) and Cobra slim. MTX, methotrexate; mg, milligram; RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies.

Figure 2 Identification of antigenic targets via Serological antigen selection (SAS)

The RA cDNA phage display library is incubated with pooled RA serum, allowing the formation of antigen-antibody complexes between IgG in the RA serum and their target antigens displayed on the surface of the phage. These complexes are captured on a solid surface using anti-human IgG antibodies, followed by washing away the non-bound phage particles. Retained phage particles are eluted, amplified and used for a new round of positive selection with RA-serum. After repeating positive selection 3 to 4 times, the eluted fraction is depleted of aspecific antibody reactivity by one round of negative selection. Here, phage is incubated with an age- and gender-matched healthy control serum pool, allowing the formation of antigen-antibody complexes between healthy control IgG and their target antigens on the phage. After this negative-affinity selection, nonbound phage particles are isolated and cDNA inserts are amplified with PCR and characterized with DNA fingerprinting and sequencing.

Figure 3 Construction of a human RA cDNA phage display library

Total RNA was independently isolated from knee synovial tissue of three different RA patients. The poly(A) mRNA was converted to first strand cDNA using a VN-anchored oligo d(T)22 primer that contained a XhoI restriction site at its 5' end. After second strand synthesis, three different adaptors were ligated to each of the blunt-end ds cDNA mixtures of the three RA patients. Each of the adaptors contained a free EcoRI overhang, used for cloning to the pSPVI vector, and either a SalI (RA-patient1), AgeI (RA-patient2) or ClaI (RA-patient3) restriction site, used for identification. The resulting cDNA molecules were size-fractionated and cloned simultaneously into the pSPVI-A, pSPVI-B and pSPVI-C phagemid vectors using EcoRI and XhoI, allowing expression of the cDNA fragments in three reading frames behind gene VI. The cDNA library was inserted in TG1 *E.coli* cells using electroporation. Phage particles displaying the human cDNA-encoded proteins were assembled and released after superinfection of TG1 cells with M13KO7 helper phage. ds, double stranded; X, XhoI; E, EcoRI, S, SalI; A, AgeI; C, ClaI; V, dA, dG or dC; N, dT, dA, dG or dC.

Figure 4 Characterization of the cDNA library clones

From a representative sample of the entire cDNA library, the inserts of 70 randomly selected bacterial clones have been characterized. The insert was amplified via PCR using general primers in the regions flanking the cDNA insert and the sequence was determined starting from gene VI. (a) The region directly behind gene VI determines the reading frame of the cDNA insert. pSPVI-B and pSPVI-C respectively have one and two extra basepairs in this region, compared to the pSPVI-A vector. The reading frame was determined of all 70 clones, including the clones containing empty pSPVI vector. (b) Each insert-containing clone (n=58) could be traced back to one of the three synovial tissue donors using our RA-patient-specific adaptors. (c) For each insert-containing clone (n=58), the region of the cDNA transcript that was fused to gene VI was determined. cDNA inserts originating from mRNA transcripts could be fused at their 5'UTR, coding region or 3'UTR. Inserts not originating from mRNA, but form rRNA or genomic DNA were also retrieved. UTR, untranslated region; mRNA, messenger RNA; rRNA, ribosomal RNA

4. References

1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62 (9):2569-2581. doi:10.1002/art.27584

2. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, PG DEG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2):295-306. doi:10.1111/j.1538-7836.2006.01753.x

3. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA, Jr., Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Muller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Ellen Csuka M, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 72 (11):1747-1755. doi:10.1136/annrheumdis-2013-204424

4. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP,

Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG, Jr., Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G, Jr., Magder LS (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64 (8):2677-2686. doi:10.1002/art.34473

5. Bournia VK, Vlachoyiannopoulos PG (2012) Subgroups of Sjogren syndrome patients according to serological profiles. J Autoimmun 39 (1-2):15-26. doi:10.1016/j.jaut.2012.03.001 6. Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B (2014) Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun 48-49:143-148. doi:10.1016/j.jaut.2014.01.003

7. Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M, Zochling J, Sahhar J, Nash P, Roddy J, Hill C, Nikpour M, Stevens W, Proudman SM, Walker JG (2015) Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis. Arthritis Rheumatol 67 (12):3234-3244. doi:10.1002/art.39316

8. Damoiseaux J, Andrade LE, Fritzler MJ, Shoenfeld Y (2015) Autoantibodies 2015: From diagnostic biomarkers toward prediction, prognosis and prevention. Autoimmun Rev 14 (6):555-563. doi:10.1016/j.autrev.2015.01.017

9. Racanelli V, Prete M, Musaraj G, Dammacco F, Perosa F (2011) Autoantibodies to intracellular antigens: generation and pathogenetic role. Autoimmun Rev 10 (8):503-508. doi:10.1016/j.autrev.2011.03.001

10. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA (2005) Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 11 (1):85-89. doi:10.1038/nm1167

11. Lindsey JW, deGannes SL, Pate KA, Zhao X (2016) Antibodies specific for Epstein-Barr virus nuclear antigen-1 cross-react with human heterogeneous nuclear ribonucleoprotein L. Mol Immunol 69:7-12. doi:10.1016/j.molimm.2015.11.007

12. Rowley MJ, Whittingham SF (2015) The Role of Pathogenic Autoantibodies in Autoimmunity. Antibodies 4 (4):314-353. doi:10.3390/antib4040314

13. Nandakumar KS, Svensson L, Holmdahl R (2003) Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. Am J Pathol 163 (5):1827-1837. doi:10.1016/S0002-9440(10)63542-0

14. Khachigian LM (2006) Collagen antibody-induced arthritis. Nat Protoc 1 (5):2512-2516. doi:10.1038/nprot.2006.393

15. Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC (2010) Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci U S A 107 (46):19985-19990. doi:10.1073/pnas.1014074107

16. McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC (2013) Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol 14 (4):327-336. doi:10.1038/ni.2548

17. Hueber W, Kidd BA, Tomooka BH, Lee BJ, Bruce B, Fries JF, Sonderstrup G, Monach P, Drijfhout JW, van Venrooij WJ, Utz PJ, Genovese MC, Robinson WH (2005) Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 52 (9):2645-2655. doi:10.1002/art.21269

18. Dromey JA, Weenink SM, Peters GH, Endl J, Tighe PJ, Todd I, Christie MR (2004) Mapping of epitopes for autoantibodies to the type 1 diabetes autoantigen IA-2 by peptide phage display and molecular modeling: overlap of antibody and T cell determinants. J Immunol 172 (7):4084-4090 19. Larman HB, Zhao Z, Laserson U, Li MZ, Ciccia A, Gakidis MA, Church GM, Kesari S, Leproust EM, Solimini NL, Elledge SJ (2011) Autoantigen discovery with a synthetic human peptidome. Nat Biotechnol 29 (6):535-541. doi:10.1038/nbt.1856

20. Larman HB, Laserson U, Querol L, Verhaeghen K, Solimini NL, Xu GJ, Klarenbeek PL, Church GM, Hafler DA, Plenge RM, Nigrovic PA, De Jager PL, Weets I, Martens GA, O'Connor KC, Elledge SJ (2013) PhIP-Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis. J Autoimmun 43:1-9. doi:10.1016/j.jaut.2013.01.013

21. Auger I, Balandraud N, Rak J, Lambert N, Martin M, Roudier J (2009) New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA. Ann Rheum Dis 68 (4):591-594. doi:10.1136/ard.2008.096917

22. Somers V, Govarts C, Somers K, Hupperts R, Medaer R, Stinissen P (2008) Autoantibody profiling in multiple sclerosis reveals novel antigenic candidates. J Immunol 180 (6):3957-3963 23. Klareskog L, Catrina AI, Paget S (2009) Rheumatoid arthritis. Lancet 373 (9664):659-672. doi:10.1016/S0140-6736(09)60008-8

24. Bartok B, Firestein GS (2010) Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 233 (1):233-255. doi:10.1111/j.0105-2896.2009.00859.x

25. Nurmohamed MT, Heslinga M, Kitas GD (2015) Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 11 (12):693-704. doi:10.1038/nrrheum.2015.112

26. Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M (2016) A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. doi:10.1007/s00296-015-3415-x

27. van den Hoek J, Roorda LD, Boshuizen HC, Tijhuis GJ, van den Bos GA, Dekker J (2016) Physical and Mental Functioning in Patients with Established Rheumatoid Arthritis over an 11year Followup Period: The Role of Specific Comorbidities. J Rheumatol 43 (2):307-314. doi:10.3899/jrheum.150536

28. Chemin K, Klareskog L, Malmstrom V (2016) Is rheumatoid arthritis an autoimmune disease? Curr Opin Rheumatol 28 (2):181-188. doi:10.1097/BOR.0000000000253

29. Barra L, Pope JE, Orav JE, Boire G, Haraoui B, Hitchon C, Keystone EC, Thorne JC, Tin D, Bykerk VP, Investigators C (2014) Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. J Rheumatol 41 (12):2361-2369. doi:10.3899/jrheum.140082

30. Franklin EC, Holman HR, Muller-Eberhard HJ, Kunkel HG (1957) An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J Exp Med 105 (5):425-438

31. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423 (6937):356-361. doi:10.1038/nature01661

32. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146 (11):797-808

33. Sutton B, Corper A, Bonagura V, Taussig M (2000) The structure and origin of rheumatoid factors. Immunol Today 21 (4):177-183

34. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416 (6881):603-607. doi:10.1038/416603a

35. Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ (2002) Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 46 (4):906-912

36. van Venrooij WJ, van Beers JJ, Pruijn GJ (2008) Anti-CCP Antibody, a Marker for the Early Detection of Rheumatoid Arthritis. Ann N Y Acad Sci 1143:268-285. doi:10.1196/annals.1443.013

37. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48 (10):2741-2749. doi:10.1002/art.11223

38. Goeb V, Jouen F, Gilbert D, Le Loet X, Tron F, Vittecoq O (2009) Diagnostic and prognostic usefulness of antibodies to citrullinated peptides. Joint Bone Spine 76 (4):343-349. doi:10.1016/j.jbspin.2008.12.006

39. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 50 (3):709-715. doi:10.1002/art.20044

40. Aubart F, Crestani B, Nicaise-Roland P, Tubach F, Bollet C, Dawidowicz K, Quintin E, Hayem G, Palazzo E, Meyer O, Chollet-Martin S, Dieude P (2011) High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J Rheumatol 38 (6):979-982. doi:10.3899/jrheum.101261

41. Lopez-Longo FJ, Oliver-Minarro D, de la Torre I, Gonzalez-Diaz de Rabago E, Sanchez-Ramon S, Rodriguez-Mahou M, Paravisini A, Monteagudo I, Gonzalez CM, Garcia-Castro M, Casas MD, Carreno L (2009) Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 61 (4):419-424. doi:10.1002/art.24390

42. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, Uffmann M, Smolen JS (2007) Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 46 (2):342-349. doi:10.1093/rheumatology/kel237

43. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7 (5):R949-958. doi:10.1186/ar1767

44. Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, Jakobsson PJ, Baum W, Nimmerjahn F, Szarka E, Sarmay G, Krumbholz G, Neumann E, Toes R, Scherer HU, Catrina AI, Klareskog L, Jurdic P, Schett G (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122 (5):1791-1802. doi:10.1172/JCI60975

45. Visser K, Verpoort KN, van Dongen H, van der Kooij SM, Allaart CF, Toes RE, Huizinga TW, van der Helm-van Mil AH (2008) Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis. Ann Rheum Dis 67 (8):1194-1195. doi:10.1136/ard.2008.088070

46. Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loet X, Tebib J, Sibilia J, Taoufik Y, Dougados M, Mariette X (2011) B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 63 (4):933-938. doi:10.1002/art.30233

47. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, Levarht NE, van der Helm-van Mil AH, Cerami A, Huizinga TW, Toes RE, Trouw LA (2011) Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 108 (42):17372-17377. doi:10.1073/pnas.1114465108

48. Willemze A, Toes RE, Huizinga TW, Trouw LA (2012) New biomarkers in rheumatoid arthritis. Neth J Med 70 (9):392-399

49. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA, Hazen SL (2007) Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 13 (10):1176-1184. doi:10.1038/nm1637

50. Somers K, Geusens P, Elewaut D, De Keyser F, Rummens JL, Coenen M, Blom M, Stinissen P, Somers V (2011) Novel autoantibody markers for early and seronegative rheumatoid arthritis. J Autoimmun 36 (1):33-46. doi:10.1016/j.jaut.2010.10.003

51. De Winter LM, Hansen WL, Van Steenbergen HW, Geusens P, Lenaerts J, Somers K, Stinissen P, van der Helm-van Mil AH, somers V (in press) Autoantibodies to two novel peptides in seronegative and early rheumatoid arthritis. Rheumatology (Oxford)

52. Magalhaes R, Stiehl P, Morawietz L, Berek C, Krenn V (2002) Morphological and molecular pathology of the B cell response in synovitis of rheumatoid arthritis. Virchows Arch 441 (5):415-427. doi:10.1007/s00428-002-0702-1

53. Mewar D, Wilson AG (2006) Autoantibodies in rheumatoid arthritis: a review. Biomed Pharmacother 60 (10):648-655. doi:10.1016/j.biopha.2006.09.002

54. Trouw LA, Mahler M (2012) Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev 12 (2):318-322. doi:10.1016/j.autrev.2012.05.007

55. van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ (2002) Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 4 (2):87-93

56. Verschueren P, Westhovens R (2011) Optimal care for early RA patients: the challenge of translating scientific data into clinical practice. Rheumatology (Oxford) 50 (7):1194-1200. doi:10.1093/rheumatology/ker131

57. Westhovens R, Verschueren P (2012) Rheumatoid arthritis: defining remission in patients with RA in clinical practice. Nat Rev Rheumatol 8 (8):445-447. doi:10.1038/nrrheum.2012.111 58. van Nies JA, Krabben A, Schoones JW, Huizinga TW, Kloppenburg M, van der Helm-van Mil AH (2014) What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 73 (5):861-870. doi:10.1136/annrheumdis-2012-203130

59. Deighton C, O'Mahony R, Tosh J, Turner C, Rudolf M, Guideline Development G (2009) Management of rheumatoid arthritis: summary of NICE guidance. BMJ 338:b702. doi:10.1136/bmj.b702

60. Singh JA, Saag KG, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 68 (1):1-26. doi:10.1002/art.39480

61. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73 (3):492-509. doi:10.1136/annrheumdis-2013-204573

62. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van den Brink HR, Schouten HJ, van der Heijde DM, Boonen A, van der Linden S (1997) Randomised comparison of combined step-

down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350 (9074):309-318. doi:10.1016/S0140-6736(97)01300-7

63. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Peeters AJ, de Jonge-Bok JM, Mallee C, de Beus WM, de Sonnaville PB, Ewals JA, Breedveld FC, Dijkmans BA (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146 (6):406-415

64. Gorter SL, Bijlsma JW, Cutolo M, Gomez-Reino J, Kouloumas M, Smolen JS, Landewe R (2010) Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69 (6):1010-1014. doi:10.1136/ard.2009.127332

65. Esselens G, Westhovens R, Verschueren P (2009) Effectiveness of an integrated outpatient care programme compared with present-day standard care in early rheumatoid arthritis. Musculoskeletal Care 7 (1):1-16. doi:10.1002/msc.136

66. Verschueren P, Esselens G, Westhovens R (2008) Daily practice effectiveness of a stepdown treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford) 47 (1):59-64. doi:10.1093/rheumatology/kem288

67. Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C (2010) Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care Res (Hoboken) 62 (8):1128-1143. doi:10.1002/acr.20188

68. Kooloos WM, Huizinga TW, Guchelaar HJ, Wessels JA (2010) Pharmacogenetics in treatment of rheumatoid arthritis. Curr Pharm Des 16 (2):164-175

69. Alarcon GS (2000) Methotrexate use in rheumatoid arthritis. A Clinician's perspective. Immunopharmacology 47 (2-3):259-271

70. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, et al. (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 (8930):1105-1110

71. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10 (13):4025-4031

72. Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89 (20):9784-9788

73. Willrich MA, Murray DL, Snyder MR (2015) Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl Res 165 (2):270-282. doi:10.1016/j.trsl.2014.09.006

74. Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, Gossec L, Landewe R, Smolen JS, Buch MH (2014) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73 (3):516-528. doi:10.1136/annrheumdis-2013-204577

75. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (25):2572-2581. doi:10.1056/NEJMoa032534

76. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353 (11):1114-1123. doi:10.1056/NEJMoa050524

77. Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev (1):CD005121. doi:10.1002/14651858.CD005121.pub3

78. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R, Investigators O (2008) Effect of interleukin-6 receptor inhibition with

tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebocontrolled, randomised trial. Lancet 371 (9617):987-997. doi:10.1016/S0140-6736(08)60453-5

79. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, Worthy G, Landewe R, Smolen JS, Emery P, Buch MH (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69 (6):976-986. doi:10.1136/ard.2009.126573

80. Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, Luyten FP, Corluy L, Houssiau FA, Verschueren P (2007) Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 56 (12):3919-3927. doi:10.1002/art.23055

81. De Cock D, Van der Elst K, Meyfroidt S, Verschueren P, Westhovens R (2015) The optimal combination therapy for the treatment of early rheumatoid arthritis. Expert Opin Pharmacother 16 (11):1615-1625. doi:10.1517/14656566.2015.1056735

82. Meyfroidt S, Hulscher M, De Cock D, Van der Elst K, Joly J, Westhovens R, Verschueren P (2015) A maximum difference scaling survey of barriers to intensive combination treatment strategies with glucocorticoids in early rheumatoid arthritis. Clin Rheumatol 34 (5):861-869. doi:10.1007/s10067-015-2876-3

83. Meyfroidt S, Van der Elst K, De Cock D, Joly J, Westhovens R, Hulscher M, Verschueren P (2015) Patient experiences with intensive combination-treatment strategies with glucocorticoids for early rheumatoid arthritis. Patient Educ Couns 98 (3):384-390. doi:10.1016/j.pec.2014.11.011

84. Meyfroidt S, van Hulst L, De Cock D, Van der Elst K, Joly J, Westhovens R, Hulscher M, Verschueren P (2014) Factors influencing the prescription of intensive combination treatment strategies for early rheumatoid arthritis. Scand J Rheumatol 43 (4):265-272. doi:10.3109/03009742.2013.863382

85. Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Van der Elst K, Meyfroidt S, Westhovens R, Care RAsg (2015) Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Res Ther 17:97. doi:10.1186/s13075-015-0611-8

86. Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R (2015) Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis 74 (1):27-34. doi:10.1136/annrheumdis-2014-205489

87. Caporali R, Pallavicini FB, Filippini M, Gorla R, Marchesoni A, Favalli EG, Sarzi-Puttini P, Atzeni F, Montecucco C (2009) Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 8 (3):274-280. doi:10.1016/j.autrev.2008.11.003

88. O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, Anis AH, Leatherman S, Keystone E, Investigators CR (2013) Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 369 (4):307-318. doi:10.1056/NEJMoa1303006

89. Van der Elst K, Meyfroidt S, De Cock D, De Groef A, Binnard E, Moons P, Verschueren P, Westhovens R (2015) Unraveling patient-preferred health and treatment outcomes in early rheumatoid arthritis: A longitudinal qualitative study. Arthritis Care Res (Hoboken). doi:10.1002/acr.22824

90. De Cock D, Meyfroidt S, Joly J, Van der Elst K, Westhovens R, Verschueren P, Care RAsg (2014) A detailed analysis of treatment delay from the onset of symptoms in early rheumatoid arthritis patients. Scand J Rheumatol 43 (1):1-8. doi:10.3109/03009742.2013.805242

91. Meyfroidt S, Stevens J, De Lepeleire J, Westhovens R, De Cock D, Van der Elst K, Vanhaecht K, Verschueren P (2015) A general practice perspective on early rheumatoid arthritis management: A qualitative study from Flanders. Eur J Gen Pract 21 (4):231-237. doi:10.3109/13814788.2015.1084279

92. De Cock D, Vanderschueren G, Meyfroidt S, Joly J, Van der Elst K, Westhovens R, Verschueren P (2014) The performance of matrices in daily clinical practice to predict rapid radiologic progression in patients with early RA. Semin Arthritis Rheum 43 (5):627-631. doi:10.1016/j.semarthrit.2013.09.004

93. Geens E, Geusens P, Vanhoof J, Berghs H, Praet J, Esselens G, Lens S, Dufour JP, Vandenberghe M, Van Mullem X, Westhovens R, Verschueren P (2009) Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria. Rheumatology (Oxford) 48 (5):546-550. doi:10.1093/rheumatology/kep018

94. Durnez A, Vanderschueren G, Lateur L, Westhovens R, Verschueren P (2011) Effectiveness of initial treatment allocation based on expert opinion for prevention of rapid radiographic progression in daily practice of an early RA cohort. Ann Rheum Dis 70 (4):634-637. doi:10.1136/ard.2010.135319

95. Verschueren P, Esselens G, Westhovens R (2009) Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study. Scand J Rheumatol 38 (3):166-172. doi:10.1080/03009740802484846

96. Verstappen SM, van Albada-Kuipers GA, Bijlsma JW, Blaauw AA, Schenk Y, Haanen HC, Jacobs JW, Utrecht Rheumatoid Arthritis Cohort Study G (2005) A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 64 (1):38-43. doi:10.1136/ard.2003.014928

97. Romao VC, Canhao H, Fonseca JE (2013) Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? BMC Med 11:17. doi:10.1186/1741-7015-11-17

98. Ponchel F, Goeb V, Parmar R, El-Sherbiny Y, Boissinot M, El Jawhari J, Burska A, Vital EM, Harrison S, Conaghan PG, Hensor E, Emery P (2014) An immunological biomarker to predict MTX response in early RA. Ann Rheum Dis 73 (11):2047-2053. doi:10.1136/annrheumdis-2013-203566

99. Peres RS, Liew FY, Talbot J, Carregaro V, Oliveira RD, Almeida SL, Franca RF, Donate PB, Pinto LG, Ferreira FI, Costa DL, Demarque DP, Gouvea DR, Lopes NP, Queiroz RH, Silva JS, Figueiredo F, Alves-Filho JC, Cunha TM, Ferreira SH, Louzada-Junior P, Cunha FQ (2015) Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis. Proc Natl Acad Sci U S A 112 (8):2509-2514. doi:10.1073/pnas.1424792112

100. Tan W, Wang F, Guo D, Ke Y, Shen Y, Lv C, Zhang M (2014) High serum level of haptoglobin is associated with the response of 12 weeks methotrexate therapy in recent-onset rheumatoid arthritis patients. Int J Rheum Dis. doi:10.1111/1756-185X.12380

101. Levitsky A, Erlandsson MC, van Vollenhoven RF, Bokarewa MI (2015) Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial. BMC Med 13:247. doi:10.1186/s12916-015-0485-2

102. Bokarewa M, Brink M, Erlandsson M, Rantapaa Dahlqvist S (2014) Survivin but not Fmslike tyrosine kinase 3 ligand is up-regulated before the onset of rheumatoid arthritis: a pilot study. Arthritis Res Ther 16 (1):R45. doi:10.1186/ar4474

103. Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228 (4705):1315-1317

104. Sundell GN, Ivarsson Y (2014) Interaction analysis through proteomic phage display. Biomed Res Int 2014:176172. doi:10.1155/2014/176172

105. Rakonjac J, Bennett NJ, Spagnuolo J, Gagic D, Russel M (2011) Filamentous Bacteriophage: Biology, Phage Display and Nanotechnology Applications. Curr Issues Mol Biol 13 (2):51-75

106. Hufton SE, Moerkerk PT, Meulemans EV, de Bruine A, Arends JW, Hoogenboom HR (1999) Phage display of cDNA repertoires: the pVI display system and its applications for the selection of immunogenic ligands. J Immunol Methods 231 (1-2):39-51

107. Somers K, Stinissen P, Somers V (2009) Optimization of high-throughput autoantibody profiling for the discovery of novel antigenic targets in rheumatoid arthritis. Ann N Y Acad Sci 1173:92-102. doi:10.1111/j.1749-6632.2009.04654.x

108. Govarts C, Somers K, Hupperts R, Stinissen P, Somers V (2007) Exploring cDNA phage display for autoantibody profiling in the serum of multiple sclerosis patients: optimization of the selection procedure. Ann N Y Acad Sci 1109:372-384. doi:10.1196/annals.1398.043

109. Georgieva Y, Konthur Z (2011) Design and screening of M13 phage display cDNA libraries. Molecules 16 (2):1667-1681. doi:10.3390/molecules16021667

110. Qi H, Lu H, Qiu HJ, Petrenko V, Liu A (2012) Phagemid vectors for phage display: properties, characteristics and construction. J Mol Biol 417 (3):129-143. doi:10.1016/j.jmb.2012.01.038

111. Vieira J, Messing J (1987) Production of single-stranded plasmid DNA. Methods Enzymol 153:3-11

112. Rondot S, Koch J, Breitling F, Dubel S (2001) A helper phage to improve single-chain antibody presentation in phage display. Nat Biotechnol 19 (1):75-78. doi:10.1038/83567

113. Hust M, Meysing M, Schirrmann T, Selke M, Meens J, Gerlach GF, Dubel S (2006) Enrichment of open reading frames presented on bacteriophage M13 using hyperphage. Biotechniques 41 (3):335-342

114. Crameri R, Suter M (1993) Display of biologically active proteins on the surface of filamentous phages: a cDNA cloning system for selection of functional gene products linked to the genetic information responsible for their production. Gene 137 (1):69-75

115. Jespers LS, Messens JH, De Keyser A, Eeckhout D, Van den Brande I, Gansemans YG, Lauwereys MJ, Vlasuk GP, Stanssens PE (1995) Surface expression and ligand-based selection of cDNAs fused to filamentous phage gene VI. Biotechnology (N Y) 13 (4):378-382

116. Somers VA, Brandwijk RJ, Joosten B, Moerkerk PT, Arends JW, Menheere P, Pieterse WO, Claessen A, Scheper RJ, Hoogenboom HR, Hufton SE (2002) A panel of candidate tumor antigens in colorectal cancer revealed by the serological selection of a phage displayed cDNA expression library. J Immunol 169 (5):2772-2780

117. Govarts C, Somers K, Hupperts R, Stinissen P, Somers V (2009) Analysis of antibody reactivity in paired cerebrospinal fluid and serum of a relapsing remitting multiple sclerosis patient. Autoimmunity 42 (8):699-704. doi:10.3109/08916930903176513

118. Rouwette M, Somers K, Govarts C, De Deyn PP, Hupperts R, Van Wijmeersch B, De Jong BA, Verbeek MM, Van Pesch V, Sindic C, Villar LM, Alvarez-Cermeno JC, Stinissen P,

Somers V (2012) Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome. J Neurochem 123 (4):568-577. doi:10.1111/jnc.12005

119. Ydens E, Palmers I, Hendrix S, Somers V (2016) The Next Generation of Biomarker Research in Spinal Cord Injury. Mol Neurobiol. doi:10.1007/s12035-016-9757-x

120. Somers K, Govarts C, Stinissen P, Somers V (2009) Multiplexing approaches for autoantibody profiling in multiple sclerosis. Autoimmun Rev 8 (7):573-579. doi:10.1016/j.autrev.2009.02.001

121. Rouwette M, Noben JP, Van Horssen J, Van Wijmeersch B, Hupperts R, Jongen PJ, Verbeek MM, De Deyn PP, Stinissen P, Somers V (2013) Identification of coronin-1a as a novel antibody target for clinically isolated syndrome and multiple sclerosis. J Neurochem 126 (4):483-492. doi:10.1111/jnc.12335

122. Ciavatta DJ, Yang J, Preston GA, Badhwar AK, Xiao H, Hewins P, Nester CM, Pendergraft WF, 3rd, Magnuson TR, Jennette JC, Falk RJ (2010) Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest 120 (9):3209-3219. doi:10.1172/JCI40034

123. Becker KG, Mattson DH, Powers JM, Gado AM, Biddison WE (1997) Analysis of a sequenced cDNA library from multiple sclerosis lesions. J Neuroimmunol 77 (1):27-38

124. Schaller M, Burton DR, Ditzel HJ (2001) Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nat Immunol 2 (8):746-753. doi:10.1038/90696

125. Steiner G, Hartmuth K, Skriner K, Maurer-Fogy I, Sinski A, Thalmann E, Hassfeld W, Barta A, Smolen JS (1992) Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. J Clin Invest 90 (3):1061-1066. doi:10.1172/JCI115921

126. Muraki Y, Matsumoto I, Chino Y, Hayashi T, Suzuki E, Goto D, Ito S, Murata H, Tsutsumi A, Sumida T (2004) Glucose-6-phosphate isomerase variants play a key role in the generation of anti-GPI antibodies: possible mechanism of autoantibody production. Biochem Biophys Res Commun 323 (2):518-522. doi:10.1016/j.bbrc.2004.08.123

127. Konig MF, Giles JT, Nigrovic PA, Andrade F (2016) Antibodies to native and citrullinated RA33 (hnRNP A2/B1) challenge citrullination as the inciting principle underlying loss of tolerance in rheumatoid arthritis. Ann Rheum Dis. doi:10.1136/annrheumdis-2015-208529

128. Dybwad A, Forre O, Natvig JB, Sioud M (1995) Structural characterization of peptides that bind synovial fluid antibodies from RA patients: a novel strategy for identification of disease-related epitopes using a random peptide library. Clin Immunol Immunopathol 75 (1):45-50

129. Araujo GR, Vaz ER, Fujimura PT, Fonseca JE, de Lima LM, Canhao H, Venturini G, Cardozo KH, Carvalho VM, Napimoga MH, Goulart LR, Goncalves J, Ueira-Vieira C (2015) Improved serological detection of rheumatoid arthritis: a highly antigenic mimotope of carbonic anhydrase III selected in a murine model by phage display. Arthritis Res Ther 17:168. doi:10.1186/s13075-015-0685-3

130. Khan AS, Wilcox AS, Hopkins JA, Sikela JM (1991) Efficient Double-Stranded Sequencing of Cdna Clones Containing Long Poly(a) Tails Using Anchored Poly(Dt) Primers. Nucleic Acids Research 19 (7):1715-1715. doi:DOI 10.1093/nar/19.7.1715

131. Clamp M, Fry B, Kamal M, Xie X, Cuff J, Lin MF, Kellis M, Lindblad-Toh K, Lander ES (2007) Distinguishing protein-coding and noncoding genes in the human genome. Proc Natl Acad Sci U S A 104 (49):19428-19433. doi:10.1073/pnas.0709013104

132. Ezkurdia I, Juan D, Rodriguez JM, Frankish A, Diekhans M, Harrow J, Vazquez J, Valencia A, Tress ML (2014) Multiple evidence strands suggest that there may be as few as 19,000 human protein-coding genes. Hum Mol Genet 23 (22):5866-5878. doi:10.1093/hmg/ddu309

133. Ota T, Katsuki I (1998) Ferritin subunits in sera and synovial fluids from patients with rheumatoid arthritis. J Rheumatol 25 (12):2315-2318

134. Telfer JF, Brock JH (2002) Expression of ferritin, transferrin receptor, and non-specific resistance associated macrophage proteins 1 and 2 (Nramp1 and Nramp2) in the human rheumatoid synovium. Ann Rheum Dis 61 (8):741-744

135. Yui S, Nakatani Y, Mikami M (2003) Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull 26 (6):753-760

136. Kang KY, Woo JW, Park SH (2014) S100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with rheumatoid arthritis. Korean J Intern Med 29 (1):12-19. doi:10.3904/kjim.2014.29.1.12

137. Trabandt A, Gay RE, Fassbender HG, Gay S (1991) Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis. Arthritis Rheum 34 (11):1444-1451

138. Grau S, Richards PJ, Kerr B, Hughes C, Caterson B, Williams AS, Junker U, Jones SA, Clausen T, Ehrmann M (2006) The role of human HtrA1 in arthritic disease. J Biol Chem 281 (10):6124-6129. doi:10.1074/jbc.M500361200

139. Tong B, Wan B, Wei Z, Wang T, Zhao P, Dou Y, Lv Z, Xia Y, Dai Y (2014) Role of cathepsin B in regulating migration and invasion of fibroblast-like synoviocytes into inflamed tissue from patients with rheumatoid arthritis. Clin Exp Immunol 177 (3):586-597. doi:10.1111/cei.12357

140. Homan EP, Rauch F, Grafe I, Lietman C, Doll JA, Dawson B, Bertin T, Napierala D, Morello R, Gibbs R, White L, Miki R, Cohn DH, Crawford S, Travers R, Glorieux FH, Lee B (2011) Mutations in SERPINF1 cause osteogenesis imperfect a type VI. J Bone Miner Res 26 (12):2798-2803. doi:10.1002/jbmr.487

141. Murray-Rust TA, Kerr FK, Thomas AR, Wu T, Yongqing T, Ong PC, Quinsey NS, Whisstock JC, Wagenaar-Bos IC, Freeman C, Pike RN (2009) Modulation of the proteolytic activity of the complement protease C1s by polyanions: implications for polyanion-mediated acceleration of interaction between C1s and SERPING1. Biochem J 422 (2):295-303. doi:10.1042/BJ20090198

142. Borghese F, Clanchy FI (2011) CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease. Expert Opin Ther Targets 15 (3):237-251. doi:10.1517/14728222.2011.550879

143. Gu R, Santos LL, Ngo D, Fan H, Singh PP, Fingerle-Rowson G, Bucala R, Xu J, Quinn JM, Morand EF (2015) Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis. Cytokine 72 (2):135-145. doi:10.1016/j.cyto.2014.11.015

144. Morand EF, Leech M (2005) Macrophage migration inhibitory factor in rheumatoid arthritis. Front Biosci 10:12-22